The trading price of BioLineRx Ltd. (NASDAQ:BLRX) closed higher on Friday, Jun 04, closing at $2.74, 4.01% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $2.7200 and $2.9300. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 0. In examining the 52-week price action we see that the stock hit a 52-week high of $6.34 and a 52-week low of $1.4. Over the past month, the stock has suffered -24% in value.
BioLineRx Ltd., whose market valuation is $122.64 Million at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.15 per share this quarter, however they have predicted annual earnings per share of -$0.84 for 2021 and -$0.57 for 2022. It means analysts are expecting annual earnings per share growth of -0.53% this year and -0.32% next year.
On the technical side, indicators suggest BLRX has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a Hold, while an average of long term indicators suggests that the stock is currently 25% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned BLRX a recommendation rating is 3. Out of them, no one rate it a Hold, while 3 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged BioLineRx Ltd. (BLRX) as Underperform, while not any of them advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that BLRX’s price is currently -6.06% off the SMA20 and -4.72% off the SMA50. The RSI metric on the 14-day chart is currently showing 45.8, and weekly volatility stands at 5.15%. When measured over the past 30 days, the indicator reaches 7.6%. BioLineRx Ltd. (NASDAQ:BLRX)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 0.32. With analysts defining $10-$19 as the low and high price targets, we arrive at a consensus price target of $13 for the trailing 12-month period. The current price is about 250.88% off the estimated low and 566.67% off the forecast high, based on this estimate. Investors will be thrilled if BLRX’s share price rises to $10, which is the median consensus price. At that level, BLRX’s share price would be +250.88% above current price.
To see how BioLineRx Ltd. stock has been performing in comparison to its peers in the industry, here are the numbers: BLRX stock’s performance was +4.01% in the latest trading, and +66.67% in the past year, while Zoetis Inc Cl A (ZTS) has traded +0.79% on the day and positioned +24.68% higher than it was a year ago. Another comparable company Takeda Pharmaceutical Co. Ltd (TAK) saw its stock close 0.66% higher in the most recent trading session but was down -9.13% in a year. Furthermore, Catalent Inc (CTLT) showed an increase of 4.01% on the day while its price kept rising at 66.67% over the past year. BioLineRx Ltd. has a P/E ratio of 0, compared to Zoetis Inc Cl A’s 47.24 and Takeda Pharmaceutical Co. Ltd’s 31.79. Also in last trading session, the S&P 500 Index has surged 0.88%, while the Dow Jones Industrial also saw a positive session, up +0.52% on the day.
An evaluation of the daily trading volume of BioLineRx Ltd. (NASDAQ:BLRX) indicates that the 3-month average is 5.28 Million. However, this figure has declined over the past 10 days to an average of 1.24 Million.
Currently, records show that 45.52 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 0% of outstanding shares, whereas institutions hold 20.86%. The stats also highlight that short interest as of May 13, 2021, stood at 559.5 Million shares, resulting in a short ratio of 0.04 at that time. From this, we can conclude that short interest is 1.23% of the company’s total outstanding shares. It is noteworthy that short shares in May were up slightly from the previous month’s figure, which was 401.16 Million. However, since the stock’s price has seen +13.1% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.